# A Study to Find a Suitable Dose of Exl-111 for Further Research

> **NCT07356713** · PHASE1 · RECRUITING · sponsor: **Excellergy Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Allergic Disease

## Interventions

- **DRUG:** Exl-111 (SAD)
- **DRUG:** Exl-111 (MAD)
- **DRUG:** Placebo
- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT07356713
- **Lead sponsor:** Excellergy Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2026-12-07
- **Final completion:** 2026-12-07
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07356713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07356713, "A Study to Find a Suitable Dose of Exl-111 for Further Research". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07356713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*